Mr Masafumi Nogimori, speach at the closing session
Mr Masafumi Nogimori Representative Director, Chairman of the Board, Astellas Pharma Inc., and Vice President of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) Global health conference “Investing for Healthier Societies: Innovation, Inclusiveness and Sustainability” that the IFPMA is hosting in partnership with Devex (4 November 2014, New York) (www.ifpmaassembly2014.org). Thank you very much...
Read moreWHA 68, Item 15.1 Antimicrobial resistance
Item 15.1 Antimicrobial resistance Delivered by Nina Grundmann, Policy Analyst, Global Health Policy, IFPMA Thank you for the opportunity to contribute to this important discussion. IFPMA represents leading research-based pharmaceutical companies as well as national and regional industry associations across the world. IFPMA commends WHO for its efforts to generate a Global Action Plan to...
Read moreOur take on Zika virus
Our take on Zika virus Geneva, 3 March 2016 − The International Federation of Pharmaceutical Manufacturers and Associations, IFPMA, which includes some of the world’s leading manufacturers of vaccines, confirms that there is currently no approved vaccine or treatment for Zika virus (ZIKV) available. On 1 February 2016, the World Health Organization (WHO) declared the...
Read moreWHA 69, Item 16.2: Follow-up to the report of the Consultative Expert Working Group
WHA 69, Item 16.2: Follow-up to the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination Delivered by Mario Ottiglio, Director, Public Affairs, Communications and Global Health Policy, IFPMA Thank you for the opportunity to contribute to this important discussion today. IFPMA represents leading research-based pharmaceutical companies as well as...
Read more10th annual G-FINDER report: Pharmaceutical industry R&D investment funding for neglected diseases continues to be a good news story
10th annual G-FINDER report: Pharmaceutical industry R&D investment funding for neglected diseases continues to be a good news story Geneva, 13 December 2017: IFPMA, the international association representing the research-based biopharmaceutical companies, welcomes the 10th annual G-FINDER report[i] results that show industry contributed USD 497m to global R&D efforts, accounting for 16% of total...
Read moreIFPMA Statement at WHA72 agenda item 11.7 Access to medicines and vaccines
IFPMA, supported by ICBA, share the goal of WHO and its Members to ensure appropriate access to affordable and quality-assured medicines and vaccines as a key component of UHC. We appreciate WHO’s efforts to develop the Roadmap, which could be a useful tool in providing greater clarity between various activities by the Organization. We also...
Read moreIFPMA Statement on the G-FINDER report 2019
G-FINDER report: Investment in neglected disease R&D by multinational pharmaceutical companies grew by more than a quarter in 2018, reaching its highest-ever level Geneva, 30 January 2020: IFPMA, the global R&D biopharmaceutical industry association, welcomes the 2019 G-FINDER report, which tracks public, private and philanthropic investment into product R&D for neglected diseases. The report shows...
Read moreGlobal Biopharmaceutical Industry Commitment to Address Coronavirus Public Health Crisis
As part of the global health community, biopharmaceutical companies are committed to playing the greatest possible role in the global response to COVID-19.
Read morePharma industry body joins as founding partner a new global collaboration to accelerate the development, production and equitable access to new COVID-19 tools
The world’s leading biopharmaceutical companies proclaimed their commitment to a landmark global partnership launched today and designed to accelerate the development and production of safe, effective and affordable therapeutics and vaccines available for all in a way that ensures nobody is left behind in the fight against COVID-19.
Read moreWHO AFRO 70th REGIONAL MEETING Agenda item: 6 “Special event on the COVID-19 response in the WHO African Region”
Geneva, August 25, 2020 IFPMA thanks the WHO AFRO for this opportunity to share a statement at this 70th session of the WHO Regional meeting. IFPMA represents leading research-based biopharmaceutical companies and national and regional industry associations across the world, including Africa. IFPMA believes that a well-coordinated, inclusive, multi-stakeholder approach and solidarity are the only...
Read more